Drugs / VAX-24
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05266456 | Feb 2022 → Jan 2023 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05844423 | Mar 2023 → Aug 2025 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05297578 | Jun 2022 → Feb 2023 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX-24 | “VAX-24 is a 24-valent pneumococcal conjugate vaccine (PCV) containing eCRM, a proprietary carrier protein with non-native amino acids (para-azidomethyl-L-phenylalanine) that...” PMID 39025698 ↗ Jul 20242“We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197...” PMID 38061367 ↗ Dec 2023 |
| Known as | 24-valent pneumococcal conjugate vaccine | “We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197...” PMID 38061367 ↗ Dec 2023 |
| Modality | Vaccine | “We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine)” PMID 38061367 ↗ Dec 2023 |
| Route | Intramuscular | “Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.” NCT05266456 ↗ |